Moxifloxacin for the treatment of pulmonary tuberculosis in children: A single center experience
- 8 February 2013
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 49 (4) , 372-376
Abstract
Objective To report our experience on the safety and tolerability of moxifloxacin for treating children affected by pulmonary TB. Study Design Children receiving a moxifloxacin-containing anti-TB regimen were included in the study. Their medical records were revised at the end of follow-up. Methods We describe nine children treated with moxifloxacin for pulmonary TB at Regina Margherita Children's Hospital (Turin, Italy) between 2007 and 2012. Moxifloxacin was administered orally at 10 mg/kg/day once daily (maximum dose = 400 mg/day) following World Health Organization indications. During treatment, patients were systematically assessed for the development of side effects. Results Eight children were considered cured at the end of treatment; one child was lost to follow-up after 3 months of treatment. Two children had side effects during treatment: one developed arthritis of the ankle; the other had liver toxicity, whose relationship with moxifloxacin could not be ruled out. We did not observe any case of QT prolongation, central nervous system disorders, growth defects or gastrointestinal disturbances. Conclusions A moxifloxacin-containing regimen might be considered for the treatment of TB in children, especially for drug-resistant and extensive forms. However, vigilance for possible side effects is recommended, especially if other drugs are concomitantly used. Studies on wider populations are needed to better define the impact of long-term treatments with quinolones on children's growth and psychomotor development and to outline regulatory indications on moxifloxacin use in the pediatric setting. Pediatr Pulmonol. 2014; 49:372–376.Keywords
This publication has 19 references indexed in Scilit:
- Pediatric tuberculosisCurrent Opinion in Pediatrics, 2012
- Paediatric use of second-line anti-tuberculosis agents: A reviewTuberculosis, 2012
- Management of multidrug-resistant tuberculosis in children: a survival guide for paediatriciansPaediatric Respiratory Reviews, 2011
- Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic dataJournal of Antimicrobial Chemotherapy, 2010
- Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialThe Lancet, 2009
- Fluoroquinolones for the Treatment of Pulmonary TuberculosisDrugs, 2007
- Fluoroquinolones for treating tuberculosis2004
- Clinical Use of Fluoroquinolones in ChildrenAnnals of Pharmacotherapy, 2000
- Quinolone Arthropathy in Animals Versus ChildrenClinical Infectious Diseases, 1997
- Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acidsToxicology Letters, 1977